Zacks Investment Research on MSN
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study
Shares of uniQure N.V. QURE skyrocketed 247.7% on Wednesday after the company reported meeting key goals in the pivotal early ...
An experimental gene therapy was found to slow the progression of Huntington’s disease in a “pivotal” study, according to ...
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first European participants have been randomized in ...
News-Medical.Net on MSN
New molecular signatures map the stepwise development of gastric cancer
Gastric cancer often develops through a gradual sequence of changes, beginning with superficial gastritis and advancing ...
CON and UK SME?ImmBio partner reach key stage in development of new pneumococcal disease vaccine: Liverpool, UK Wednesday, September 17, 2025, 12:00 Hrs [IST] The Infection Inno ...
Over 60% of patients who received ervogastat plus clesacostat for 48 weeks achieved MASH resolution without fibrosis worsening. The combination was associated with a worsening fasting lipid and ...
Following the apparent elimination of a late-stage gene therapy study last week, Swiss drug juggernaut Roche has confirmed that it’s axing a hemophilia candidate inherited in its 2019 buyout of Spark ...
Brepocitinib remains “ahead of competition” in the dermatomyositis space, according to analysts at Leerink, who projected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback